Media Coverage
Bolt Bio Adds $93.5M to Move Ahead Immune-Stimulating Cancer Drugs
Xconomy
Bolt Bio Adds $93.5M to Move Ahead Immune-Stimulating Cancer Drugs
Xconomy
Piramal Pharma Solutions and Bolt Biotherapeutics Sign Production Agreement
ADC Review
U.S. Patent for Bolt Biotherapeutics’ Boltbody™ ISAC Platform Technology is a Major Milestone in the Development of BDC-1001
ADC Review
Randall Schatzman, Ph.D. to Lead Growth of Immune- Stimulating Antibody Conjugates at Bolt Biotherapeutics
ADC Review
How the Next Generation Antibody Drug Conjugates Expands Beyond Cytotoxic Payloads for Cancer Therapy
ADC Review
Bolt Biotherapeutics Nabs $93.5M to Push Provenge Inventor’s New Idea Deeper in the Clinic
Endpoints News
Bolt’s Myeloid Twist on ADCs Charged up with $93.5M series C
BioCentury
Pfizer-Backed Bolt Therapeutics Strikes $93.5M Funding Round As Lead Med Hits the Clinic
Fierce Biotech
Agonist ecstasy? HER2 (and more) ‘Bolt’-on strategy draws $93.5M series C
BioWorld
Bolt Biotherapeutics Initiates Immunotherapy Trial of Lead Drug Candidate in HER2-Expressing Solid Tumors
Precision Oncology News